Cover Image

BCL6 enables Ph+ acute lymphoblastic leukaemia cells to survive BCR-ABL1 kinase inhibition

Show other versions (1)

Targeted cancer therapies are often associated with drug resistance, a phenomenon that has been observed with tyrosine kinase inhibitors (TKIs), widely used to treat leukaemia driven by BCR-ABL1 mutations. Markus Mueschen and colleagues describe a novel BCL6-dependent mechanism of drug resistance in...

Full description

Saved in:
Bibliographic Details
Main Authors: Duy, Cihangir (Author) , Hurtz, Christian (Author) , Shojaee, Seyedmehdi (Author) , Cerchietti, Leandro (Author) , Geng, Huimin (Author) , Swaminathan, Srividya (Author) , Klemm, Lars (Author) , Kweon, Soo-mi (Author) , Nahar, Rahul (Author) , Braig, Melanie (Author) , Park, Eugene (Author) , Kim, Yong-mi (Author) , Hofmann, Wolf-Karsten (Author) , Herzog, Sebastian (Author) , Jumaa, Hassan (Author) , Koeffler, H. Phillip (Author) , Yu, J. Jessica (Author) , Heisterkamp, Nora (Author) , Graeber, Thomas G. (Author) , Wu, Hong (Author) , Ye, B. Hilda (Author) , Melnick, Ari (Author) , Müschen, Markus (Author)
Format: Article (Journal) Editorial
Language:English
Published: 19 May 2011
In: Nature
Year: 2011, Volume: 473, Issue: 7347, Pages: 384-388
ISSN:1476-4687
DOI:10.1038/nature09883
Online Access:Verlag, lizenzpflichtig, Volltext: https://doi.org/10.1038/nature09883
Verlag, lizenzpflichtig, Volltext: https://www.nature.com/articles/nature09883
Get full text
Author Notes:Cihangir Duy, Christian Hurtz, Seyedmehdi Shojaee, Leandro Cerchietti, Huimin Geng, Srividya Swaminathan, Lars Klemm, Soo-mi Kweon, Rahul Nahar, Melanie Braig, Eugene Park, Yong-mi Kim, Wolf-Karsten Hofmann, Sebastian Herzog, Hassan Jumaa, H. Phillip Koeffler, J. Jessica Yu, Nora Heisterkamp, Thomas G. Graeber, Hong Wu, B. Hilda Ye, Ari Melnick, Markus Müschen
Description
Summary:Targeted cancer therapies are often associated with drug resistance, a phenomenon that has been observed with tyrosine kinase inhibitors (TKIs), widely used to treat leukaemia driven by BCR-ABL1 mutations. Markus Mueschen and colleagues describe a novel BCL6-dependent mechanism of drug resistance in leukaemia through which TKI-induced upregulation of BCL6 allows leukemia cells to cope with acute oncogene withdrawal. Targeted inhibition of BCL6 reduces the number of drug-resistant and self-renewing leukaemia-initiating cells. In xenograft models of acute lymphoblastic leukaemia cells carrying BCR-ABL1 mutations, dual inhibition of BCR-ABL1 and BCL6 prevents resistance and improves the anticancer response.
Item Description:Veröffentlicht: 18. Mai 2011
Gesehen am 14.04.2026
Im Titel ist das Pluszeichen hochgestellt
Physical Description:Online Resource
ISSN:1476-4687
DOI:10.1038/nature09883

Similar Items